US2019175656A1PendingUtilityA1
Mesenchymal stromal cells and uses related thereto
Assignee: ASTELLAS INST FOR REGENERATIVE MEDICINEPriority: Nov 30, 2011Filed: Sep 7, 2018Published: Jun 13, 2019
Est. expiryNov 30, 2031(~5.3 yrs left)· nominal 20-yr term from priority
C12N 2501/155C12N 5/0647C12N 2533/90C12N 2501/26C12N 2501/165C12N 2506/02C12N 5/0662C12N 2506/11C12N 2501/145C12N 2501/125C12N 2501/115A61K 35/28A61K 45/06A61K 48/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical preparation suitable for use in a mammalian patient, comprising at least 10 6 mesenchymal stromal cells and a pharmaceutically acceptable carrier, wherein the mesenchymal stromal cells have replicative capacity to undergo (a) at least 10 population doublings in cell culture with less than 25 percent of the cells undergoing cell death, senescing or differentiating into non-MSC cells by the tenth doubling, or (b) at least 5 passages in cell culture with less than 25 percent of the cells undergoing cell death, senescing or differentiating into fibroblasts by the 5th passage.
2 . (canceled)
3 . A pharmaceutical preparation comprising at least 10 6 mesenchymal stromal cells and a pharmaceutically acceptable carrier, wherein the mesenchymal stromal cells are differentiated from a hemangioblast cell.
4 . A cryogenic cell bank comprising at least 10 6 mesenchymal stromal cells, wherein the mesenchymal stromal cells have replicative capacity to undergo at least 10 population doublings in cell culture with less than 25 percent of the cells undergoing cell death, senescing or differentiating into fibroblasts by the tenth population doubling.
5 .- 45 . (canceled)
46 . A method for generating mesenchymal stromal cells of the preparation of claim 2 comprising culturing hemangioblasts under conditions that give rise to mesenchymal stem cells.
47 .- 82 . (canceled)
83 . Mesenchymal stromal cells derived from hemangioblasts obtained by the method of claim 46 .
84 .- 103 . (canceled)
104 . A kit comprising the preparation of mesenchymal stromal cells of claim 1 , wherein said cells or preparation of cells are frozen or cryopreserved, or wherein said cells or preparation of cells is contained in a cell delivery vehicle.
105 . (canceled)
106 . A method for treating a disease or disorder, comprising administering an effective amount of the preparation of mesenchymal stromal cells according to claim 1 to a subject in need thereof.
107 - 112 . (canceled)
113 . A method of treating bone loss or cartilage damage comprising administering an effective amount of the preparation of mesenchymal stromal cells according to claim 1 to a subject in need thereof.
114 - 125 . (canceled)Join the waitlist — get patent alerts
Track US2019175656A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.